Skip to content

A cohort study to explore the efficacy of double-layer artificial dermal repair materials for plastic wounds based on real-world data

A cohort study to explore the efficacy of double-layer artificial dermal repair materials for plastic wounds based on real-world data

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100055057
Enrollment
Unknown
Registered
2021-12-31
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Full-thickness skin defect wounds of extremities requiring plastic surgery due to scar contracture, acute defect, congenital deformity, birthmark and giant mole excision

Interventions

Queue one:Receive simultaneous transplantation of double-layer artificial dermal repair material combined with autologous thin skin
Queue two:Receive an autologous full-thickness skin graft

Sponsors

Ruijin Hospital Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Those who voluntarily participate in this clinical study and sign the informed consent; 2. Commit to abide by the research procedures and cooperate with the implementation of the whole process of research; 3. Plastic wounds that need to be transplanted with dermal matrix; 4. Conform to specific laboratory test results; 5. Be able to adhere to and cooperate with surgical treatment and follow-up throughout the later period; 6. If it is a child-bearing woman, she should use contraception for at least one month before the screening, and promise to take contraception throughout the study period and continue to the specified time after the end of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects whose infection has not been controlled after debridement and treatment of the wound; 2. The pathological diagnosis of the wound surface is suspected or confirmed to be malignant tumor; 3. Malignant tumor research subjects, or those who need to receive radiotherapy and chemotherapy during the research period; 4. Subjects with poorly controlled diabetes (fasting blood glucose is still >=7.0mmol/L after drug control, or glycated hemoglobin HbA1c >=12%, and transaminase> 1.5 times the upper limit of the normal value and other diabetic complications); 5. Those with severe heart, liver, kidney and other organ or system dysfunction that cannot tolerate surgery; 6. Subjects allergic to bovine collagen and chondroitin sulfate; 7. Other researchers think that it is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Skin graft survival rate;

Secondary

MeasureTime frame
One-time survival rate of skin grafting;Wound shrinkage rate;Vancouver Scar Scale after Wound Surgery;Functional evaluation of joint range of motion in the skin graft area;Evaluation of qualitative recovery of skin graft area function;

Countries

China

Contacts

Public ContactLiu Yan

Ruijin Hospital Shanghai Jiaotong University School of Medicine

rjliuyan@126.com+86 13801831868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026